Blue Jet Healthcare Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/oe9b8rqxetrmq7qaqb32wnto.pdf

Key Takeaways


Financial Performance & Margin Drivers

Shiven Arora: "Both of them would be positively contributing for FY27, which is backed by some customer orders. And you have seen in the past year, we have been able to scale up both the molecules well."

Product & Pipeline Dynamics

VK Singh: "It is not that supplies from Blue Jet are not going and somebody else is supplying. Or the end molecule is not doing well. So it is neither the case."

CDMO & Late-Stage Pipeline

Shiven Arora: "There is something very encouraging cooking, but I think we would be in a position to share that in the next quarter."

Capacity Expansion & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Contrast media commercial launchIodinated contrast media product launch and ramp-upFY27, from Q1 onwards
Mahad Unit-3 qualificationCore block ready for validationsQ1 FY27
Hyderabad R&D center operationalDevelopment work to commenceQ3 FY27
New sweetener exhibit batchesPilot quantities to be produced for continuous engineering indicatorsFY27
Late-stage asset contributionAbout six late-stage assets to start contributingApproximately two years from now
Destocking realignmentChannel inventory and supply chain for Bempedoic acid to normalizeA couple of quarters
New API/PI product updatePositive update to be sharedNext quarter
FY27 CAPEX targetsSpecific targets to be providedNext quarter

Key Metrics

MetricQ3 FY26
Revenue from operations₹192.4 cr, decreased 40% YoY from ₹318.4 cr
Revenue from operations QoQ+16%, increase mainly from contrast media dispatches recognized
Gross margin52%, lower than normal trend due to product mix and one-time inventory write-off
EBITDA margin24%, lower due to operating leverage, labor code implementation, and foreign consultants
EBITDAdecreased 62% YoY
PATdecreased 39% YoY
Nine months revenue from operations+3% YoY, increase due to higher PI sales
Nine months gross margin53%, compared to 50% last year
Nine months other income₹4.5 cr
Cumulative CAPEX at Mahad Unit-3approx. ₹146 cr incurred to-date
Vizag Greenfield total investment plan₹1,000 cr over next three to four years
New Hyderabad R&D center investmentabout ₹40 cr
Cash balance₹410 cr as of December
Active RFPs trackedaround 20, including six high conviction phase-3 programs
Power from renewable sources70% of consumption met through wind and solar